Logo for Anavex Life Sciences Corp

Anavex Life Sciences Investor Relations Material

Latest events

Logo for Anavex Life Sciences Corp

Q1 2025

Anavex Life Sciences
Logo for Anavex Life Sciences

Q1 2025

12 Feb, 2025
Logo for Anavex Life Sciences

Investor Presentation

14 Jan, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Anavex Life Sciences Corp

Access all reports
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. The company's lead drug candidate is 2-73 that has completed phase II clinical trial for the treatment of Alzheimer's disease. Its programs also includes ANAVEX 3-71, which is in pre-clinical testing for the treatment of amyotrophic lateral sclerosis disease; and ANAVEX 1-41, a pre-clinical stage small molecule compound for the treatment of epilepsy.